L’Oreal’s Microbiome Explorations Lead To Micreos Deal For Next-Gen Antibacterial
“We expect this partnership to be groundbreaking,” says Mark Offerhaus, CEO of Micreos, which will provide L’Oreal with its proprietary endolysin, which selectively destroys microorganisms associated with skin problems while leaving beneficial bacteria intact.
You may also be interested in...
Unilever’s in vitro and clinical studies examining the effects of glycerol, an ingredient in Baby Dove wash and lotion, were inadequate to substantiate microbiome claims as consumers are likely to understand them, according to a 13 January decision from the UK-based Advertising Standards Authority.
With many competitor programs on hold during the COVID crisis, L’Oreal dialed up its media investments and launched products over the summer that were postponed from the first quarter, resulting in a return to growth in the firm’s third quarter led by Professional Products and Active Cosmetics.
Headquartered in The Hague, Netherlands, Micreos is focused on developing targeted antibacterial products to replace antibiotics, protect against food contamination and treat inflammatory skin conditions. The firm’s Gladskin Eczema Cream, now available stateside, uses a patented enzyme technology to destroy Staphylococcus aureus bacteria while leaving skin’s beneficial flora intact.